Get the Stockscreener App
1.185
1.28%
0.015
Plus Therapeutics Inc stock is traded at $1.185, with a volume of 20,600.
It is up +1.28% in the last 24 hours and down -17.71% over the past month.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
See More
Previous Close:
$1.17
Open:
$1.21
24h Volume:
20,600
Relative Volume:
0.27
Market Cap:
$6.90M
Revenue:
-
Net Income/Loss:
$-13.32M
P/E Ratio:
-0.1968
EPS:
-6.02
Net Cash Flow:
$-13.01M
1W Performance:
-0.42%
1M Performance:
-17.71%
6M Performance:
-47.10%
1Y Performance:
-54.94%
1-Day Range:
$1.17
$1.21
1-Week Range:
$1.16
$1.42
52-Week Range:
$1.145
$2.6702
Plus Therapeutics Inc Stock (PSTV) Company Profile
Name
Plus Therapeutics Inc
Sector
Industry
Phone
737.255.7194
Address
4200 MARATHON BLVD., AUSTIN, TX
Compare PSTV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| PSTV | 1.18 | 6.90M | 0 | -13.32M | -13.01M | -6.02 |
| VRTX | 467.37 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 760.78 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 564.61 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 230.58 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.54 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
| Oct-16-20 | Initiated | Maxim Group | Buy |
Plus Therapeutics Inc Stock (PSTV) Latest News
Earnings call: Plus Therapeutics reports progress and financials for Q3 2024 - Investing.com
Plus Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Plus Therapeutics Inc (PSTV) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... - Yahoo Finance
Plus: Q3 Earnings Snapshot - Houston Chronicle
Plus Therapeutics Advances Radiotherapeutics in Q3 2024 - TipRanks
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewswire
PLUS THERAPEUTICS Inc (PSTV) Quarterly 10-Q Report - Quartzy
Leptomeningeal Metastases Clinical Trials 2024: FDA - openPR
Undercovered Dozen: Asbury Automotive, Globalstar, Northland Power, Aquestive Therapeutics - Seeking Alpha
Sitravatinib Plus Nivo-Ipi Appears Safe, Active in ccRCC - Cancer Therapy Advisor
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Plus Therapeutics partners with SpectronRx for cancer therapy - Investing.com India
Plus Therapeutics partners with SpectronRx for cancer therapy By Investing.com - Investing.com UK
Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership - GlobeNewswire
Plus Thera teams up with SpectronRx for radiotherapy production - The Pharma Letter
Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024 - GlobeNewswire
Plus Therapeutics (PSTV) Sets Q3 2024 Earnings Call for November 14 | PSTV Stock News - StockTitan
Plus Therapeutics granted extension by Nasdaq - Investing.com
Leptomeningeal Metastases Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca - The Globe and Mail
Plus Therapeutics Showcases Leptomeningeal Metastases - GlobeNewswire
Simulations Plus, Inc. (NASDAQ:SLP) Receives $56.00 Consensus Price Target from Analysts - Defense World
Metastatic Colorectal Cancer Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Daiichi Sankyo Company, Mirati Therapeutics, Apollomics - Barchart
Evaluating Immunotherapy as Systemic Therapy Plus RT in Early-Stage NSCLC - Cancer Network
Colorectal Cancer Pipeline Overview 2024: FDA Approvals and Key Companies involved by DelveInsight | Novartis, Pharma Oncology, Purple Biotech Ltd, Plus Therapeutics, Processa Pharma - The Globe and Mail
Curio Digital Therapeutics Applauded by Frost & Sullivan for Enhancing Women's Maternal Mental Healthcare with its MamaLift and MamaLift Plus Solutions - The Malaysian Reserve
Prescription Digital Therapeutics for Mental Health: A New Era in Psychiatry - Psychiatry Advisor
SalioGen Therapeutics hit by layoffs, as gene-editing biotechs continue to struggle - STAT
Ultra-Hypofractionated Radiation May Mitigate Breast Cancer Recurrence - Cancer Network
Plus Therapeutics reports progress in brain cancer trial - Investing.com
Plus Therapeutics reports progress in brain cancer trial By Investing.com - Investing.com Canada
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting - ForexTV.com
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update - GlobeNewswire
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of ... - The Bakersfield Californian
Dow Tumbles Over 200 Points; Carnival Posts Upbeat Earnings - Benzinga
The 3 Best Light Therapy Lamps of 2024 | Reviews by Wirecutter - Wirecutter, A New York Times Company
Celldex drug reduces chronic hive activity, but patient discontinuations raise questions - STAT
Cipaglucosidase alfa plus miglustat: linking mechanism of action to clinical outcomes in late-onset Pompe disease - Frontiers
Elevar Therapeutics Resubmits New Drug Application to FDA - GlobeNewswire
Elevar Therapeutics Resubmits New Drug Application to FDA for Combination of Camrelizumab plus Rivoceranib as First-Line Treatment Option for Unresectable Hepatocellular Carcinoma Boosted by CARES-310 Leading Overall Survival Analysis - Yahoo Finance
Bluejay Diagnostics (NASDAQ:BJDX) versus Plus Therapeutics (NASDAQ:PSTV) Head-To-Head Review - Defense World
Plus Therapeutics to present at CNS Annual Meeting By Investing.com - Investing.com Canada
From 'science fiction to reality': New George Church-founded biotech raises $75M for cell therapy platform - Fierce Biotech
Plus Therapeutics to present at CNS Annual Meeting - Investing.com
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 - GlobeNewswire
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting - StockTitan
Gilead Sciences Therapeutic Areas: Virology, Oncology & Inflammation - Gilead Sciences
Plus Therapeutics director buys $6k worth of shares By Investing.com - Investing.com Canada
Plus Therapeutics director buys $6k worth of shares - Investing.com
Plus Therapeutics director acquires $8.5k in stock - Investing.com
Plus Therapeutics Inc Stock (PSTV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Plus Therapeutics Inc Stock (PSTV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hawkins Richard J | Director |
Sep 12 '24 |
Buy |
1.35 |
6,285 |
8,512 |
11,188 |
| Petersen Greg | Director |
Sep 11 '24 |
Buy |
1.35 |
12,500 |
16,875 |
48,921 |
| Clowes Howard | Director |
Sep 11 '24 |
Buy |
1.34 |
5,000 |
6,681 |
26,497 |
| HEDRICK MARC H | Chief Executive Officer |
Sep 10 '24 |
Buy |
1.23 |
8,000 |
9,839 |
20,425 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Sep 10 '24 |
Buy |
1.27 |
4,098 |
5,204 |
9,815 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
May 08 '24 |
Buy |
2.04 |
4,902 |
10,000 |
5,717 |
| HEDRICK MARC H | Chief Executive Officer |
May 08 '24 |
Buy |
2.04 |
12,255 |
25,000 |
12,425 |
| Petersen Greg | Director |
May 08 '24 |
Buy |
2.04 |
12,255 |
25,000 |
36,421 |
| Clowes Howard | Director |
May 08 '24 |
Buy |
2.04 |
9,804 |
20,000 |
21,497 |
| Hawkins Richard J | Director |
May 08 '24 |
Buy |
2.04 |
4,902 |
10,000 |
4,903 |
3.39%
0.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):